CAR-TCR Summit Europe 2019

CAR-TCR Summit Europe is organized by Hanson Wade and will be held from Feb 25 - 27, 2019 at Hotel Novotel London West, London, England, United Kingdom.

Who Attends:
Academic Institutions, Biotechs, Large Pharma.

The CAR-TCR Summit Europe is your opportunity to join the expert CAR and TCR pioneers to learn about never-before-seen clinical updates and novel technology to improve solid tumour targeting, advance allogeneic therapy development and automate manufacturing processes to reduce the cost of goods. 

If you are looking to initiate clinical trials in Europe, join us to navigate the complex regulations and reimbursement landscape to understand and overcome market access challenges. 

And if you are looking to drive progress in scientific discovery, join us as we discuss novel breakthroughs with innovations with gamma delta and NKT cells, innovative antigen screening platforms and genetic engineering strategies to create, translate and develop the next generation of CAR and TCR therapies.

Encapsulating this excitement, the CAR-TCR Summit Europe is providing you with the platform to learn from the experience of industry pioneers, hear novel clinical updates and network with key opinion leaders to takeaway valuable lessons learnt to improve upon your CAR-TCR pipeline.

Key topics to be addressed:
• Novel technologies to create the next generation of CAR and TCR therapies exploring Medigene ’ s genetically engineered t cells, Fate ’ s dual-targeted TCR and the progression of allogeneic development with updates from Celyad and Cellectis
• Improve solid tumour targeting with antigen identification strategies from Immatics and cutting edge engineering from Marker Therapeutics to target novel antigens and reduce off-tumour toxicity
• Automate and streamline manufacturing processes with strategies from UCL which utilize an automated high-throughput microbioreactor system to ensure process consistency
• Navigate the European regulatory challenges to initiate trials across multiple countries with advice and guidance from the EMA
• Pricing strategies to prepare for accessible reimbursements with insights shared from NICE and CEVR on the value of these potentially curative therapies

Time: 08:00 to 17:00

Prices:
Conference + Workshop Day: GBP 2498.0,
Conference Only: GBP 1699.0,
Conference + Workshop Day (Early Bird ends Friday 25th January, 2019): GBP 2398.0,
Conference Only (Early Bird ends Friday 25th January, 2019): GBP 1599.0

Speakers: Dale Ludwig, Chief Scientific Officer, Actinium Pharmaceuticals, Barbra Sasu, Chief Scientific Officer, Allogene Therapeutics, Christian Itin, Chief Executive Officer, Autolus, Vicki Coutinho, Senior Director, Regulatory Affairs, Autolus, Jie Jia, Vice President, Strategic Alliances CARsgen Therapeutics, Zonghai Li , Chief Executive Officer, CARsgen Therapeutics, Tony Ho Executive Vice President, Head of Research and Development, CRISPR Therapeutics, Stefanos Theoharis, Senior Vice President, Corporate Development and Partnering, Cell Medica, Stephane Depil, Senior Vice President Research and Development and Chief Medical, Cellectis, David Gilham, Vice President, Research and Development, Celyad, Detlev Parow Head of Department of Medicines, Therapeutic Appliances and Remedies Product and Billing Management Division, DAK-Gesundheit, Bob Valamehr Chief Development Officer and Vice President Cancer Immunotherapy, Fate Therapeutics, Cedrik Britten, Head of Oncology Cell Therapy Research Unit, GSK, Harpreet Singh, Chief Executive Officer, Immatics US, Will Singleterry Associate Director, Business Development, Isoplexis, Marc Kamp Director CAR-T Product Distribution and Supplier Quality Management, Kite Pharma, John Maher, Chief Scientific Officer, Leucid Bio, Juan Vera, Chief Development Officer, Marker Therapeutics, Peter L. Hoang, President and Chief Executive Officer, Marker Therapeutics, Dolores Schendel, Chief Executive Officer and Chief Scientific Officer, Medigene, Kai Pinkernell, Chief Medical Officer and Chief Development Officer, Medigene, James McBlane Preclinical Assessor, MHRA and Member, Committee for Advanced Therapies (CAT), EMA, Katharina Winnemöller, Marketing Manager for Clinical Cell Processing and T Cell Applications, Miltenyi Biotec, Pilar Pinilla Dominguez Senior Scientific Adviser, NICE, Therese Choquette Analytical Project Leader, Cell and Gne Therapy Development and Manufacturing, Novartis, Francesco Marincola, Chief Scientific Officer, Refuge Biotech, Jim Freeth Co-managing Director, Retrogenix, Véronique Blanc Immuno-Oncology Program Director, Servier, Michael Leek, Chief Executive Officer, TC Biopharm, Alfonso Quintás Cardama, Chief Medical Officer, TCR2 Therapeutics, Dan Ollendorf, Director Value Measurement and Global Health Initiatives, Tufts University Center for the Evaluation of Value and Risk in Health, CEVR, Qasim Rafiq, Senior Lecturer in Bioprocessing of Regenerative, Cellular and Gene Therapy, UCL, Miguel Forte Chief Executive Officer, Zelluna Immunotherapy, Laurence Cooper, Chief Executive Officer, Ziopharm Oncology, Jens Hasskarl, Senior Director, Research Development, Clinical and Medical, Celgene Corporation, Maureen Graham, Managing Director, Diamond Pharma Services, Andreas Göbel Executive and Technology Lead, Hypertrust Patient Data Care, Kai Wilkens, Senior Director Europe ACD, Bio-Techne